These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 9261947

  • 1. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ, Wu JY, Gardner BH, Anderson CA, Kensil CR, Recchia J, Coughlin RT, Powell MF.
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [Abstract] [Full Text] [Related]

  • 2. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
    Wu JY, Gardner BH, Murphy CI, Seals JR, Kensil CR, Recchia J, Beltz GA, Newman GW, Newman MJ.
    J Immunol; 1992 Mar 01; 148(5):1519-25. PubMed ID: 1538134
    [Abstract] [Full Text] [Related]

  • 3. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 4. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.
    Gorse GJ, Patel GB, Newman FK, Belshe RB, Berman PW, Gregory TJ, Matthews TJ.
    Clin Diagn Lab Immunol; 1996 Jul 10; 3(4):378-86. PubMed ID: 8807200
    [Abstract] [Full Text] [Related]

  • 5. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 10; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 6. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.
    O'Hagan DT, Ugozzoli M, Barackman J, Singh M, Kazzaz J, Higgins K, Vancott TC, Ott G.
    Vaccine; 2000 Mar 06; 18(17):1793-801. PubMed ID: 10699327
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
    Johnson RP, Hammond SA, Trocha A, Siliciano RF, Walker BD.
    J Virol; 1994 May 06; 68(5):3145-53. PubMed ID: 7908700
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120.
    Fouts TR, Tuskan RG, Chada S, Hone DM, Lewis GK.
    Vaccine; 1995 Dec 06; 13(17):1697-705. PubMed ID: 8719522
    [Abstract] [Full Text] [Related]

  • 12. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team.
    J Infect Dis; 2001 Feb 15; 183(4):563-70. PubMed ID: 11170981
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A, Lifson JD, Silverstein PS, Jia F, Sheffer D, Li Z, Narayan O.
    Virology; 2000 Aug 15; 274(1):149-64. PubMed ID: 10936096
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of the immune response to recombinant gp120 in humans and chimpanzees.
    Berman PW, Eastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, Schwartz D, Gorse G, Belshe R, Clements ML, Byrn RA.
    AIDS; 1994 May 15; 8(5):591-601. PubMed ID: 7520248
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
    Fomsgaard A, Nielsen HV, Bryder K, Nielsen C, Machuca R, Bruun L, Hansen J, Buus S.
    Scand J Immunol; 1998 Apr 15; 47(4):289-95. PubMed ID: 9600309
    [Abstract] [Full Text] [Related]

  • 18. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
    Boudet F, Keller H, Kieny MP, Thèze J.
    Mol Immunol; 1995 May 15; 32(7):449-57. PubMed ID: 7783749
    [Abstract] [Full Text] [Related]

  • 19. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Charles-Niño C, Pedroza-Roldan C, Viveros M, Gevorkian G, Manoutcharian K.
    Vaccine; 2011 Jul 18; 29(32):5313-21. PubMed ID: 21600948
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.